Ignite Creation Date:
2025-12-24 @ 5:41 PM
Ignite Modification Date:
2026-01-04 @ 3:45 AM
Study NCT ID:
NCT03398668
Status:
COMPLETED
Last Update Posted:
2019-03-13
First Post:
2018-01-08
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Combined Occipital and Supraorbital Transcutaneous Nerve Stimulation for Treatment of Migraine
Sponsor:
Neurolief Ltd.
Organization:
Study Overview
Official Title:
Combined Occipital and Supraorbital Transcutaneous Nerve Stimulation for Treatment of Migraine
Status:
COMPLETED
Status Verified Date:
2019-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study will evaluate the clinical performance and safety of a self administered abortive treatment for migraine headache using combined occipital and supraorbital transcutaneous nerve stimulator (Neurolief device, Relievion™).
Detailed Description:
None
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: